MX2021008327A - Composicion para prevenir, mejorar o tratar enfermedades o sintomas relacionados con el cartilago que comprende hapln1. - Google Patents

Composicion para prevenir, mejorar o tratar enfermedades o sintomas relacionados con el cartilago que comprende hapln1.

Info

Publication number
MX2021008327A
MX2021008327A MX2021008327A MX2021008327A MX2021008327A MX 2021008327 A MX2021008327 A MX 2021008327A MX 2021008327 A MX2021008327 A MX 2021008327A MX 2021008327 A MX2021008327 A MX 2021008327A MX 2021008327 A MX2021008327 A MX 2021008327A
Authority
MX
Mexico
Prior art keywords
composition
hapln1
relieving
preventing
symptoms
Prior art date
Application number
MX2021008327A
Other languages
English (en)
Inventor
Dae Kyong Kim
Ji Min Jang
Original Assignee
Haplnscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haplnscience Inc filed Critical Haplnscience Inc
Publication of MX2021008327A publication Critical patent/MX2021008327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Animal Husbandry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Materials For Medical Uses (AREA)
  • Fodder In General (AREA)

Abstract

La presente divulgación se refiera a una composición para la prevención, mejora o tratamiento de enfermedades o síntomas relacionados con el cartílago. La composición incluye hialuronano y proteína 1 de unión de proteoglicano (HAPLN1) como un principio activo. En detalle, la presente divulgación proporciona una composición para la regeneración del cartílago, una composición para la prevención, mejora o tratamiento de la osteoartritis o una composición para la regeneración del cartílago de la placa de crecimiento, cada composición incluye HAPLN1 como un principio activo.
MX2021008327A 2019-02-28 2019-02-28 Composicion para prevenir, mejorar o tratar enfermedades o sintomas relacionados con el cartilago que comprende hapln1. MX2021008327A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2019/002418 WO2020175721A1 (ko) 2019-02-28 2019-02-28 Hapln1을 포함하는 연골 관련 질환 또는 증상의 예방, 개선 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
MX2021008327A true MX2021008327A (es) 2021-08-11

Family

ID=72238712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008327A MX2021008327A (es) 2019-02-28 2019-02-28 Composicion para prevenir, mejorar o tratar enfermedades o sintomas relacionados con el cartilago que comprende hapln1.

Country Status (14)

Country Link
US (1) US20230158106A1 (es)
EP (1) EP3888664A4 (es)
JP (1) JP7302903B2 (es)
CN (1) CN113490500A (es)
AU (1) AU2019431082B2 (es)
BR (1) BR112021013538A2 (es)
CA (1) CA3122250C (es)
CO (1) CO2021009034A2 (es)
IL (1) IL283551A (es)
MX (1) MX2021008327A (es)
PE (1) PE20230436A1 (es)
SG (1) SG11202105767YA (es)
WO (1) WO2020175721A1 (es)
ZA (1) ZA202103815B (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130052198A1 (en) 2010-03-29 2013-02-28 The General Hospital Corporation Anti-inflammatory factors
EP2716751A1 (en) * 2012-10-08 2014-04-09 BioTime, Inc. Differentiated progeny of clonal progenitor cell lines
US10322125B2 (en) * 2013-02-22 2019-06-18 Emory University TGF-beta enhancing compositions for cartilage repair and methods related thereto
CN105636614A (zh) * 2013-09-09 2016-06-01 菲格内有限责任公司 用于软骨细胞或软骨型细胞再生的基因治疗
HUE053684T2 (hu) * 2015-01-07 2021-07-28 Pfizer Oldható FGFR3 csalik csontnövekedési rendellenességek kezelésére
AU2017207445B2 (en) * 2016-01-14 2023-12-07 Spinalcyte, Llc Cellular blend for the regeneration of chondrocytes or cartilage type cells
NZ756946A (en) * 2017-03-06 2022-07-01 Haplnscience Inc Composition for skin aging measurement, prevention, or alleviation, using hapln1
KR20190024727A (ko) * 2017-08-29 2019-03-08 중앙대학교 산학협력단 Hapln1을 유효성분으로 함유하는 연골 재생용 조성물

Also Published As

Publication number Publication date
PE20230436A1 (es) 2023-03-08
SG11202105767YA (en) 2021-06-29
US20230158106A1 (en) 2023-05-25
JP2022522144A (ja) 2022-04-14
AU2019431082A1 (en) 2021-07-01
EP3888664A1 (en) 2021-10-06
CA3122250C (en) 2023-12-12
CN113490500A (zh) 2021-10-08
CA3122250A1 (en) 2020-09-03
AU2019431082B2 (en) 2022-12-15
ZA202103815B (en) 2022-09-28
JP7302903B2 (ja) 2023-07-04
IL283551A (en) 2021-07-29
WO2020175721A1 (ko) 2020-09-03
BR112021013538A2 (pt) 2021-09-14
CO2021009034A2 (es) 2021-07-30
EP3888664A4 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
CR20210415A (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
EP4378535A3 (en) Antibiotic formulations for lower back pain
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
EP3530124A4 (en) DIET CONTAINING A SUBTILUS BACILIUS STRAIN, BACILIUS PUMILUS STRAIN AND BACILIUS LICHENFORMIS STRAIN AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING ACUTE HEPATOPANCREATIC NECROSIS DISEASE OR BLANCHANCHESIS SYNDROME
BR112012013888A2 (pt) preparados de combinação com antagonista de citocina e corticosteroide
AR118208A1 (es) Composiciones para evitar, mejorar o tratar enfermedades o síntomas relacionados con los cartílagos, que comprenden hapln1
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
PH12021550104A1 (en) High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
JOP20210295A1 (ar) أشكال صلبة لمثبط GlyT1
MX2021014773A (es) Formas de sales cristalinas de un inhibidor de cinasas.
MX2023003348A (es) Compuestos y composiciones como moduladores de señalización tlr.
BRPI0408827A (pt) composições oftálmicas preservadas
WO2022169755A8 (en) Sulfonamide substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereof
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
MX2021008327A (es) Composicion para prevenir, mejorar o tratar enfermedades o sintomas relacionados con el cartilago que comprende hapln1.
WO2021101802A3 (en) Placental tissue particulate compositions and methods of use
WO2021041324A3 (en) Compositions and methods for the treatment of pathological pain and itch
BR112021018222A2 (pt) Composição
AU2003251728A1 (en) Placental growth factor as a target for the treatment of osteoporosis
EP3848039A4 (en) PHARMACEUTICAL COMPOSITION WITH A TSP1 PROTEIN INHIBITOR AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF FABRY DISEASE
CO2021014968A2 (es) Composición para la prevención o el tratamiento de la caída del cabello que incluye hapln1
MX2023003725A (es) Composiciones farmacéuticas y usos de las mismas para la prevención y/o tratamiento de la inflamación.
MX2022015772A (es) Proteínas enpp1 o enpp3 solubles y sus usos.